Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma

Neurosciences

Volumn 18, Issue 4, 2013, Pages 349-355

  Alnaami, Ibrahim M ^a,c   Al Nuaimi, Saleem K ^a   Senthilselvan, Ambikaipakan ^a   Murtha, Albert D ^a   Walling, Simon ^b   Mehta, Vivek ^a   Gourishankar, Sita ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SEIZURE; SURVIVAL RATE; TERTIARY CARE CENTER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84940334827     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344: 114-123.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin 2007; 25: 1111-1139.
4. Mason WP, Maestro RD, Eisenstat D, Forsyth P, Fulton D, Laperrière N, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 2007; 14: 110-117.
5. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial apply?" Lancet 2005; 365: 82-93.
6. Riegelman R. Reading clinical research--what can we expect to learn from reading randomized clinical trials? Md Med 2002; 3: 35-38.
7. Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, et al. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med 2013; 2: 185-195.
8. Hoover JM, Chang SM, Parney IF. Clinical trials in brain tumor surgery. Neuroimaging Clin N Am 2010; 20: 409-424.
9. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
10. Kreth FW, Berlis A, Spiropoulou V, Faist M, Scheremet R, Rossner R, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 1999; 86: 2117-2123.
11. Scott JG, Suh JH, Elson P, Barnett GH, Vogelbaum MA, Peereboom DM, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol 2011; 13: 428-436.
12. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001; 19: 509-518.
13. Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, et al. Prognostic implication of clinical and pathologic features in patients with glioblastomamultiforme treated with concomitant radiation plus temozolomide. Tumori 2007; 93: 248-256.
14. Ozbek N, Cakir S, Gursel B, Meydan D. Prognostic significance of seizure in patients with glioblastoma multiforme. Neurol India 2004; 52: 76-78.
15. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993; 78: 767-775.
16. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009; 110: 156-162.
17. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62: 564-576.
18. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol 2001; 54: 217-224.
19. Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994; 70: 352-362.
20. Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2007: MR000009.
21. Stupp R, Weber DC. The role of radio-and chemotherapy in glioblastoma. Onkologie 2005; 28: 315-317.
22. Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol 2011; 104: 339-349.
23. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012; 107: 359-364.
24. Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 1996; 77: 1535-1543.
25. Fazeny-Dorner B, Wenzel C, Veitl M, Piribauer M, Rössler K, Dieckmann K, et al. Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs 2003; 14: 305-312.
26. Fazeny-Dorner B, Gyries A, Rossler K, Ungersböck K, Czech T, Budinsky A, et al. Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center. Wien Klin Wochenschr 2003; 115: 389-397.
27. Stark AM, van de Bergh J, Hedderich J, Mehdorn HM, Nabavi A. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg 2012; 114: 840-845.
28. Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 2008; 10: 79-87.
29. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886.
30. Prasad V, Jorgenson J, Ioannidis JP, Cifu A. Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. J Clin Epidemiol 2013; 66: 361-366.
31. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. Am J Ophthalmol 2000; 130: 688.
32. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
33. Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party. J Neurooncology 1990; 9: 47-55.